In News

Oculogica Issued Patent for Biometric Identification Using an Eye Tracking System

February 12, 2019 — NEW YORK– Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced today that the U.S. Patent and Trademark Office (USPTO) has issued the company a patent for a method of identifying patients using biometric information measured by a medical device that uses an eye tracking system. Identification of the patient may be performed by a cloud-based or local biometric service.

The patent, U.S. Patent No. 10201274, “Eye-Tracking System with Biometric Identification”, expands the company’s patent portfolio and enhances the technological capability of their eye tracking-based diagnostics by enabling automatic patient identification during an eye tracking procedure. Oculogica plans to incorporate this feature into a future version of their EyeBOX® eye tracking system, which just received marketing authorization as an aid in diagnosis of concussion last month.

“Given the inherent challenges of assessing concussion, one of the goals of our technology is to deliver objective information to patients and their healthcare providers in a way that is as seamless and efficient as possible. This innovation represents our commitment to reduce the burden in diagnosing concussion for patients and their caregivers, and our commitment to an efficient and elegant user experience,” said Rosina Samadani, Ph.D., CEO of Oculogica.

“Positively identifying patients has received increased attention in recent years with the widespread adoption of electronic medical record (EMR) systems.  This invention enables the seamless enrollment and identification of patients who receive an eye tracking test that may be used for diagnosing a number of neurological conditions including mild traumatic brain injury (mTBI),” said Daniel Sanderson, Principal Engineer of Oculogica and author of the patent.

On December 28, 2018, Oculogica was granted marketing authorization to commercialize the EyeBOX device, the first, non-invasive, baseline-free aid in the diagnosis of concussion. The EyeBOX device uses eye tracking to provide objective information to aid in assessment of patients with suspected concussion via an easy to take, 4-minute test. The EyeBOX device launched in early January to select, qualified sites. Oculogica is engaged in additional studies to assess applications in specific, emerging, concussion therapies as well as in diagnosis of other neurological conditions of the brain, such as elevated intracranial pressure.

 

About Oculogica

Oculogica, Inc. is an eye tracking-based neuro-diagnostic company founded by Dr. Uzma Samadani, Associate Professor of Neurosurgery at the University of Minnesota Medical School. The company has developed the EyeBOX device, the first non-invasive, baseline-free, aid in diagnosis of concussion to help physicians objectively evaluate patients with suspected concussions. The EyeBOX is a 4-minute test appropriate for ages 5 to 67 years. To learn more about the Company and the EyeBOX device, visit www.oculogica.com.

Oculogica, EyeBOX, and the respective logos are the trademarks and copyrights of Oculogica, Inc.

Contact:

Viridiana Juarez

484-393-2694

JAMA: Eye-Tracking Test Approved to Help Diagnose Concussion
Oculogica Receives FDA Marketing Authorization for EyeBOX® Device, the First Non-Invasive, Baseline-Free Test for Concussion